1. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

PDGF receptor beta

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

1

Natural
Products

10

Recombinant Proteins

1

Isotope-Labeled Compounds

9

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1856
    Proinsulin C-peptide (human)
    1 Publications Verification

    Insulin Receptor PDGFR MAPKAPK2 (MK2) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions .
    Proinsulin C-peptide (human)
  • HY-13894
    Tyrphostin AG1296
    3 Publications Verification

    AG1296

    PDGFR c-Kit FLT3 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range .
    Tyrphostin AG1296
  • HY-100434

    FGFR PDGFR EGFR Src TGF-β Receptor Cardiovascular Disease Cancer
    PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .
    PD-161570
  • HY-P99402

    REGN 2176

    PDGFR Cardiovascular Disease Neurological Disease
    Rinucumab (REGN 2176) is an anti-PDGFR-β antibody. Rinucumab is used for research on neovascular age-related macular degeneration .
    Rinucumab
  • HY-W011266
    JNJ-10198409
    1 Publications Verification

    PDGFR Cancer
    JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM) .
    JNJ-10198409
  • HY-112345

    FGFR PDGFR EGFR Src Cancer
    PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity .
    PD-089828
  • HY-13338

    Adrenergic Receptor Cardiovascular Disease
    Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol
  • HY-162888

    PDGFR ERK Cardiovascular Disease
    WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .
    WQ-C-401
  • HY-N0366R

    Reference Standards PDGFR Cancer
    Sennoside B (Standard) is the analytical standard of Sennoside B. This product is intended for research and analytical applications. Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia) . Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway .
    Sennoside B (Standard)
  • HY-13894R

    AG1296 (Standard)

    PDGFR c-Kit FLT3 Apoptosis Reference Standards Cardiovascular Disease Inflammation/Immunology Cancer
    Tyrphostin AG1296 (Standard) is the analytical standard of Tyrphostin AG1296. This product is intended for research and analytical applications. Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range .
    Tyrphostin AG1296 (Standard)
  • HY-112417

    PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family Cardiovascular Disease Cancer
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .
    Ki11502
  • HY-W755295

    Adrenergic Receptor Cardiovascular Disease
    Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol hydrochloride
  • HY-152051S

    Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease
    Mabuterol-d9 (hydrochloride) is deuterium labeled Mabuterol (hydrochloride). Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol-d9 hydrochloride
  • HY-W755295R

    Reference Standards Adrenergic Receptor Cardiovascular Disease
    Mabuterol (hydrochloride) (Standard) is the analytical standard of Mabuterol (hydrochloride). This product is intended for research and analytical applications. Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol hydrochloride (Standard)
  • HY-13338R

    Adrenergic Receptor Reference Standards Cardiovascular Disease
    Mabuterol (Standard) is the analytical standard of Mabuterol. This product is intended for research and analytical applications. Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol (Standard)
  • HY-19471

    Drug Isomer CDK VEGFR Survivin Apoptosis Cancer
    (rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET .
    (rac)-ZK-304709

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: